# AI biotechnology funding and development

> Live situation record from CLSTR: https://clstr.news/situations/ai-biotechnology-funding-and-development
> Updated: 2026-08-13T15:05:04.000Z. Sources: 4. Developments: 2.

Aureka Biotechnologies has secured $100 million in Series B financing, bringing its total funding to nearly $200 million. The funding round was structured in tranches, with Granite Asia exclusively funding the first tranche, followed by a subsequent tranche led by a strategic investor with participation from HighLight Capital and existing shareholders MPCi and NRL Capital.

The company plans to use the proceeds to research and train next-generation biological foundation models for tasks such as de novo molecular design, biological structure modeling, and function prediction. Aureka also intends to upgrade its ‘Lab-in-the-Loop’ platform, which integrates AI models with single-cell functional screening and high-throughput experimental validation to facilitate a continuous feedback loop for drug development.

## Timeline

### 2026-08-13: AI biotechnology firms secure major funding and partnerships

AI-driven biotech firms Aizen Therapeutics and Aureka Biotechnologies are advancing drug discovery through new collaborations and significant funding rounds totaling hundreds of millions of dollars.

2 sources. https://clstr.news/cluster/ai-biotechnology-firms-secure-major-funding-and-partnerships

### 2026-08-11: Aureka Biotechnologies raises $100 million in Series B funding

Aureka Biotechnologies raised $100 million in Series B funding to develop biological foundation models and AI-driven drug discovery infrastructure, bringing its total funding to nearly $200 million.

3 sources. https://clstr.news/cluster/aureka-biotechnologies-raises-100-million-in-series-b-funding

---
Cite as: AI biotechnology funding and development. CLSTR, https://clstr.news/situations/ai-biotechnology-funding-and-development